Rodman & Renshaw initiated coverage of Achieve Life Sciences (ACHV) with a Buy rating and $12 price target Achieve is dedicated to addressing the global smoking and nicotine addiction crisis by developing and commercializing cytisinicline, the analyst tells investors in a research note. The firm says the company is poised to address the lack of FDA-approved treatments for e-cigarette cessation, further expanding the potential impact of cytisinicline in combating nicotine addiction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences Reports Q3 2024 Progress
- Achieve Life Sciences reports Q3 EPS (36c), consensus (26c)
- Achieve Life Sciences files to sell 3.49M shares of common stock for holders
- ACHV Upcoming Earnings Report: What to Expect?
- Achieve Life Sciences CMO speaks at FDA, NIH Smoking Cessation Public Meeting